CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...
Exhibit 10.18
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER
THE SECURITIES ACT OF 1933, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
Xxxxxxxxx Xxxxx
Global Alliance Director, Pharma Partnering
Building 71 I 5.70
X.Xxxxxxxx-Xx Xxxxx Ltd
Xxxxxxxxxxxxxxxxx 000
0000, Xxxxx
Xxxxxxxxxxx
28th February 2013
Re: Amended and Restated License Agreement dated December 10, 2008 (“Agreement”) by and between Roche Palo Alto LLC, Xxxxxxxx-Xx Xxxxx Inc and X. Xxxxxxxx-Xx Xxxxx Ltd (collectively “Roche”) and Biotte Therapies Inc. (formely Synosia Therapeutics Inc.} and Biotie Therapies AG (formely Synosia Therapeutics AG) (rollectively “Biotie”).
Dear Christoph
Capitalized terms not otherwise defined shall have the meanings assigned to them in the Agreement.
On 20th October 2009, Roche and Biotie signed the 2nd Letter Agreement which gave Biotie the right to an option to expand the Tier 2 and Tier 3 Field. On 16th June 2010, Biotie informed Roche of our decision to exercise the right to obtain the option and paid the Field Expansion Option Fee of [*****]. In accordance with the 2nd Letter Agreement, the Field Expansion Exercise Fee of [*****] was due on or before 31st December 2012. On 11th September 2012, Roche and Biotie signed the 4th Letter Agreement which included an extension of the deadline for payment of the Field Expansion Exercise Fee to 30th April 2013.
Biotie is now informing Roche of our intention to exercise the Field Expansion with immediate effect, and we would request that you issue us with an invoice to allow payment of the Field Expansion Exercise Fee.
Please address the invoice to:
Biotie Therapeutics Ltd
Attn: Xx. Xxxxxxx Xxxxxxxx
VP Operations
Xxxxxxxxxxxxxxx 00
0000 Xxxxx
Yours sincerely
Biotie Therapies Inc.
/s/ Xxx X. Xxxxxx
xxx Xxxxxx, Ph.D.
Chief Operating Officer & President of US Operations
| Biotie Therapies Inc. | Tel. [*****] | |
| 000 Xxxxxxx Xxxxxxxxx | Fax. [*****] | |
| Suite 1200 | xxx.xxxxxx.xxx | |
| South Xxx Xxxxxxxxx | ||
| XX 00000, XXX |
